Understanding Breast Cancer Staging.

N.B This topic will make you understand why it is important to do monthly breast exam. The earlier the cancer is detected, the better the prognosis.

Breast cancer staging
To stage cancer, the American Joint Committee on Cancer, first places the cancer in a letter category using the tumor, nodes, metastasis (TNM) classification system. The stage of a breast cancer describes its size and the extent to which it has spread. The staging system ranges from stage 0 to stage IV according to tumor size, lymph nodes involved, and distant metastasis.

T indicates tumor size. The letter T is followed by a number from 0 to 4, which describes the size of the tumor and whether it has spread to the skin or chest wall under the breast. Higher T numbers indicate a larger tumor and/or more extensive spread to tissues surrounding the breast.

TX: The tumor cannot be assessed.
T0: No evidence of a tumor is present.
Tis: The cancer may be LCIS, DCIS, or Paget disease.
T1: The tumor is 2 cm or smaller in diameter.
T2: The tumor is 2-5 cm in diameter.
T3: The tumor is more than 5 cm in diameter.
T4: The tumor is any size, and it has attached itself to the chest wall and spread to the pectoral (chest) lymph nodes.

N indicates palpable nodes. The letter N is followed by a number from 0 to 3, which indicates whether the cancer has spread to lymph nodes near the breast and, if so, whether the affected nodes are fixed to other structures under the arm.

NX: Lymph nodes cannot be assessed (eg, lymph nodes were previously removed).
N0: Cancer has not spread to lymph nodes.
N1: Cancer has spread to the movable ipsilateral axillary lymph nodes (underarm lymph nodes on the same side as the breast cancer).
N2: Cancer has spread to ipsilateral lymph nodes (on the same side of the body as the breast cancer), fixed to one another or to other structures under the arm.
N3: Cancer has spread to the ipsilateral mammary lymph nodes or the ipsilateral supraclavicular lymph nodes (on the same side of the body as the breast cancer).

M indicates metastasis. The letter M is followed by a 0 or 1, which indicates whether the cancer has metastasized (spread) to distant organs (eg, lungs or bones) or to lymph nodes that are not next to the breast, such as those above the collarbone.

MX: Metastasis cannot be assessed.
M0: No distant metastasis to other organs is present.
M1: Distant metastasis to other organs has occurred.

About the Author

Gregory Mburu us a medical professional and a part time marketer. He post information about breast cancer and other gynaecological neoplastic disorders at http://breast-cancer-information.blogspot.com/

Written by: GREGORY MBURU

Updates and Recent News

New Program Offers Breast Cancer Clinicians And Patients Support For Pre-operative Clinical Assessment And Ongoing Surveillance Of Lymphedema
The Patient Advocate Foundation (PAF), with support from ImpediMed Ltd. , is pleased to announce the launch of the Lymphedema CareLine (LCL). PAF, through its MedCare Division, is offering the national, toll-free patient/provider hotline designed to provide information and assistance to breast cancer patients who are or may be at risk for post-treatment side effects such as lymphedema (swelling due to blockage in the lymphatic system). Staffed by a dedicated team of multilingual clinical case managers with nursing and social work experience, the LCL offers personal case management services, including the dissemination of information about lymphedema, navigation through the reimbursement system, interpretation of a patients' health insura.
To Read More...

DNA Repair Company Announces New Clinical Findings Which May Help To Guide Breast Cancer Treatment
BOSTON -- The DNA Repair Company (DNAR), an early-stage company focused on personalized approaches to cancer treatment, announced today that it has identified a promising set of protein biomarkers that may aid in the treatment of a particularly aggressive form of breast cancer. These findings were presented at the CTRC-AACR San Antonio Breast Cancer Symposium. The DNAR study was conducted in collaboration with investigators from the Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center, both in Boston. The lead author of the study, Brian Alexander, MD, physician resident at the Harvard Radiation Oncology Program and currently a White House Fellow, was selected as a recipient of the prestigious AstraZenec.
To Read More...